Something wrong? Let us know
Checked
Federal dataHealth
Larotrectinib
Published by U.S. Food and Drug Administration · Updated 03/17/2025 · Yearly
- Last updated
- 03/17/2025
- First published 09/16/2016
- Update frequency
- Yearly
- Formats
- Web only
- Coverage
- Nationwide
- Federal data
About this dataset
Vitrakvi (larotrectinib) is an oral solution that inhibits tropomyosin receptor kinases, prescribed for certain cancers with NTRK gene fusions. It's a 20 mg/mL concentrate manufactured by Bayer HealthCare Pharmaceuticals Inc. and approved under NDA211710 in December 2022. This information was generated using AI and is provided for informational and research purposes only.
Files and access
Links open the official government source
- Larotrectinibaccessdata.fda.govWeb page
Links open outside websites we do not control.
Frequently asked questions
- Who publishes Larotrectinib?
- U.S. Food and Drug Administration, part of U.S. Department of Health & Human Services, publishes this dataset on Data.gov.
- How often is it updated?
- The publisher lists the update frequency as yearly. The last update was on 03/17/2025.
- How do I download it?
- Use the official source link above to view or request the data.
Similar data from other publishers
- LarotrectinibState of VirginiaVitrakvi (larotrectinib) is an oral solution that inhibits tropomyosin receptor kinases, prescribed for certain cancers with NTRK gene fusions. It's a 20 mg/mL concentrate manufactured by Bayer HealthCare Pharmaceuticals Inc. and approved under NDA211710 in DeUpdated 06/12/2026
- LarotrectinibState of VirginiaVitrakvi (larotrectinib) is an oral solution that inhibits tropomyosin receptor kinases, prescribed for certain cancers with NTRK gene fusions. It's a 20 mg/mL concentrate manufactured by Bayer HealthCare Pharmaceuticals Inc. and approved under NDA211710 in DeUpdated 09/29/2026
- EntrectinibState of VirginiaRozlytrek (entrectinib) is an oral prescription drug by Genentech, Inc., used to treat certain cancers like lung cancer with ROS1 gene changes or solid tumors with NTRK fusions. It comes as 50 mg pellets in dose packs. This information was generated using AI aUpdated 03/24/2026
- EntrectinibState of VirginiaRozlytrek (entrectinib) is an oral prescription drug by Genentech, Inc., used to treat certain cancers like lung cancer with ROS1 gene changes or solid tumors with NTRK fusions. It comes as 50 mg pellets in dose packs. This information was generated using AI aUpdated 09/29/2026
- LazertinibState of VirginiaLazcluze (lazertinib) is an oral prescription tablet medication classified as a kinase inhibitor. It is available in 80mg and 240mg strengths and is manufactured by Janssen Biotech, Inc. for treating specific conditions like certain cancers. This information wUpdated 07/06/2026
Where this catalog comes from
- Data.gov CatalogU.S. General Services Administration
- State and local open data portalsSocrata Discovery API
- State and city CKAN portalsCalifornia, Virginia, Boston, Houston and more
- Government ArcGIS Hub sitesCity and county GIS data
Catalog checked 10/24/2026
We list dataset descriptions only. Downloads and APIs link straight to the official government source, which holds the current version and its terms of use.
Source: Data.gov · Last updated 10/24/2026 · Listing only; the data stays with the publisher
Share: